SARS-CoV-2

[Immunological Reviews] The disease ranges in severity from asymptomatic through to severe acute respiratory distress requiring intensive care treatment and mechanical ventilation, which can lead to respiratory failure and death.

[Science Advances] Using Syrian hamsters that modeled moderate to severe COVID-19 disease, the authors demonstrated the high efficacy of PiN-21 to prevent and treat SARS-CoV-2 infection.

[Nature Communications] Using a comprehensive translational approach, researchers unraveled the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies.

[Cell Reports] Investigators established an efficient human alveolosphere culture method and sphere-based drug testing platform for SARS-CoV-2.

[Neuroscientist] With advancement of organoid technology, brain organoids offer a promising tool for unravelling pathophysiologic clues and potential therapeutic options for neuropsychiatric complications of COVID-19.

[Nature News] Since the SARS-CoV-2 variant known as B.1.617 was first reported in India late last year, it has spread to dozens of other countries- including the United States, Singapore and the United Kingdom, where it has become dominant in some regions.